Menu
Menu
What does it take for a 130-year-old company to remain at the forefront of pharmaceutical innovation?
In this episode of Decoded, Dr. Jurgi Camblong sits down with André Hoffmann, Vice-Chair of Roche and the fourth generation of the Hoffmann family to lead the company since 1896, to discuss how genomics and AI are transforming pharmaceutical innovation and what organizational structures enable long-term thinking in business.
André has spent his career at one of the world's largest pharmaceutical companies, observing how the industry is adapting to new technologies and changing approaches to drug discovery. He brings perspective on how companies can invest in long-term innovation cycles, the strategic considerations of different ownership models, and how businesses measure value and impact.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
